Breast Cancer
Conditions
Keywords
breast cancer, honey, blood
Brief summary
Study aim Determination of the effect of a honey based (HB) syrup on the blood parameters of patients with breast cancer Design Two arm parallel group randomised clinical trial, double blinded Settings and conduct Design of the study: Women patients with breast cancer referring to Shohaday-e- Tajrish Hospital of Tehran who are under chemotherapy treatment. In order to blind the investigator, medications are named as A for syrup of HB and B for placebo. The patients don't aware of the type of drug they are assigned to. In addition, the groups are entered into statistical analysis as A and B. The patients will revive either A or B syrup for 4 weeks. At the beginning of the trial demographic data would be gathered. Also, a blood sample would be drawn at the beginning time and after the end of intervention period (week 4). Data would be analysed by SPSS software using T-test.
Detailed description
Women patients with breast cancer referring to Shohaday-e- Tajrish Hospital of Tehran who are under chemotherapy treatment. In order to blind the investigator, medications are named as A for syrup of HB and B for placebo. The patients don't aware of the type of drug they are assigned to. In addition, the groups are entered into statistical analysis as A and B. The patients will revive either A or B syrup for 4 weeks. At the beginning of the trial demographic data would be gathered. Also, a blood sample would be drawn at the beginning time and after the end of intervention period (week 4). Data would be analysed by SPSS software using T-test. Main outcome variables The mean of score of Hemoglobine (Hb), 2. The mean of score of white blood cell count (WBC), 3. The mean of score of platelet count (Plt) Main outcome variables The mean of score of Hemoglobine (Hb), 2. The mean of score of white blood cell count (WBC), 3. The mean of score of platelet count (Plt) Participants/Inclusion and exclusion criteria Inclusion criteria: women suffer from breast cancer who are; 1.Age between 18- 70 years old; 2. Hemoglobin level is at least 8g/dl; 3. Hematocrit level at least 30%; 4. normal TSH. Exclusion criteria: 1. Heart disease with unstable conditions; 2. Disabling Pulmonary Disease and History of Asthma; 3. Severe kidney disease; 4. Creatinine level greater than 2mg/dl; 5. Proteinuria; 6. The SGOT level more than 3 times of the normal threshold; 7. Bilirubin levels greater than 2mg/dl; 8. Positive history of hypersensitivity to saffron, rose water and honey; 9. severe infection; 10. Systemic disease;11. Positive history of gout or high level of uric acid; 12. An individual who uses antidepressants due to depression; 13. Simultaneous use of drugs that affect fatigue; 14. Uncontrolled pain; 15. Unwillingness to participate in the study.
Interventions
DRUGhoney based (HB) syrup
honey-based syrup is prepared according to the documented Persian Medicine manuscripts with some modifications. HB is a mixture of honey, rose water and saffron. Each 100g of HB consisted of 79.87 g honey, 19.97 g rose water, and 0.16 g saffron. All the ingredients were licensed and approved by The Islamic Republic of Iran Food and Drug Organization (I.R.I.FDO).
Sponsors
Shahid Beheshti University of Medical Sciences
Shiraz University of Medical Sciences
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* Female gender * Age between 18- 70 years old Patients * known case of breast cancer * Hemoglobin level is at least 8 g / dl * Hematocrit level at least 30% The level of * TSH is normal
Exclusion criteria
* Patients known case of heart disease with unstable conditions * Disabling Pulmonary Disease and History of Asthma * Patients known case of severe kidney disease (Creatinine level is greater than 2mg / dl Proteinuria) * The SGOT level is more than 3 times of the normal threshold * Bilirubin levels is greater than 2mg / dl * Positive history of hypersensitivity to saffron, Rose water and Honey * Uncontrolled pain * severe infection * serious illness * Positive history of gout or high level of uric acid * An individual who uses antidepressants due to depression * Simultaneous use of drugs that affect blood cells * Unwillingness to participate in the study * Active treatment for anemia (transfusion or Epoetin Alfa Injection)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The change of mean score of Hemoglobin level of patients in intervention and placebo groups | The weeks of 0 and 4 after treatment | A mean score of hemoglobin level is generally defined as 12.5 to 14.5 grams per deciliter (125-145 grams per liter) for women. Higher or lower scores mean a worse outcome. |
| The change of mean score of WBC count of patients in intervention and placebo groups | The weeks of 0 and 4 after treatment | A mean score of WBC count is usually between 4,000 and 11,000 per microliter of blood for women. Higher or lower scores mean a worse outcome. |
| The change of mean score of Plt count of patients in intervention and placebo groups | The weeks of 0 and 4 after treatment | A mean score of Plt count is usually ranges from 150,000 to 450,000 platelets per microliter of blood for women. Higher or lower scores mean a worse outcome. |
Countries
Iran
Outcome results
None listed